A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/ quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type.
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
NIHR Mental Health BioResource for Depression and Anxiety
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
Neurological Long-term Conditions: Online Integrated Care Platform Study
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
Real-world performance evaluation of PreSize Neurovascular medical software in a clinical setting
MND Register for England, Wales and Northern Ireland
NIHR Mental Health BioResource for Depression and Anxiety
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
NIHR Mental Health BioResource for Depression and Anxiety
Developing the Clinical Anxiety Screen for people with Severe to Profound Intellectual Disabilities (CIASP-ID)
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
MND Register for England, Wales and Northern Ireland
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
MND Register for England, Wales and Northern Ireland
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
NIHR Mental Health BioResource for Depression and Anxiety
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
MND Register for England, Wales and Northern Ireland
MND Register for England, Wales and Northern Ireland
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
MND Register for England, Wales and Northern Ireland
NIHR Mental Health BioResource for Depression and Anxiety
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
NIHR Mental Health BioResource for Depression and Anxiety
Developing the Clinical Anxiety Screen for people with Severe to Profound Intellectual Disabilities (CIASP-ID)
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
NIHR Mental Health BioResource for Depression and Anxiety
NIHR Mental Health BioResource for Depression and Anxiety
NIHR Mental Health BioResource for Depression and Anxiety
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
MND Register for England, Wales and Northern Ireland